Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Open Access

Circadian variation in MGMT promoter methylation and expression predicts sensitivity to Temozolomide in glioblastoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMaria F. Gonzalez-AponteYHYitong HuangWLWilliam A. Leidig

Discussion

Loading...

Member takes

Overview

Analysis reveals how daily rhythms in MGMT methylation and expression influence Temozolomide effectiveness in glioblastoma.

Key Points

  • Daily rhythms in MGMT-promoter methylation and protein abundance influence TMZ sensitivity in glioblastoma.
  • Protein levels of MGMT peaked during CT4, correlating with the most effective timing for TMZ administration.
  • Retrospective analysis verified MGMT status varied with time-of-day in biopsies from glioblastoma patients.
  • Incorporating circadian variations into a model suggests optimized TMZ dosing can enhance treatment efficacy.

Cite This Study

Gonzalez-Aponte et al. (2025) studied this question.

synapsesocial.com/papers/68c243acb210217d647a7fc6https://doi.org/10.21203/rs.3.rs-7411649/v1
View Full Paper
Ask AI
Bookmark
Share